Silicon Valley vs. Death
Tad Friend of The New Yorker presents a wide-ranging review of the various initiatives currently under way to extend healthy human lifespans - discussing the work of SENS Research Foundation, Google's Calico, Unity Biotechnology, and many others.
LysoSENS to Enter Human Trials
SRF and the Buck take on Tau
We're proud to announce a new collaboration with the Buck Institute for Research on Aging's Dr. Julie Andersen, a leading expert on neurodegeneration. The project will focus on clearing tangles of tau protein - a key driver of Alzheimer's and similar diseases.
Rejuvenating the Mitochondria
As part of Google's Giving Week, MitoSENS project leader Dr. Matthew O'Connor gave a Tech Talk on December 9th introducing SRF and our "damage repair" approach to fighting aging - followed by an update on our progress in repairing defective mitochondria.
Aging Runs In The Blood
Surgically connecting young and old mice reverses some aspects of aging, but isn't practical for humans! Fortunately for us, new SRF-funded work shows that transfusions of young blood produce many of the same benefits - paving the way towards human trials.
Check out all the latest news from SENS Research Foundation in our February newsletter. You might also like to check out the archive of past messages, or subscribe to our mailing list to make sure you don't miss out on future updates!
Faces of Cancer
During our Control ALT, Delete Cancer fundraiser, we invited donors to send us a photo of a friend or loved one whose life has been affected by, or lost to, cancer. We've assembled those images into our Faces of Cancer wall.
More Progress in Senolytics
Deleting senescent cells from mice delays many age-related diseases. A recent paper from the Unity Biotechnology team, who aim to start human trials in 12-18 months, now identifies atherosclerosis as another deadly condition which may be prevented by senolytic drugs.
Our 115-Year Shelf Life?
A recent demographic analysis in Nature by Vijg et al. has attracted global attention after concluding that there is a "natural limit" of around 115 years to human lifespans - but has also been criticised for undue pessimism regarding future medical advances.
Funding a Cure for Aging
Project|21's first patron, German internet entrepeneur Michael Greve, has formally announced a list of the research efforts that will be supported over the next year by the initial $1m tranche of his donation - as well as the startup companies receiving seed funds.
SENS Research Foundation has commissioned a series of 8 animations, narrated by actor Edward James Olmos, to explain the concept of SENS and some of the therapies that we're developing to end age-related disease for good.
Michael Greve, the first donor to our Project|21 campaign, gave a presentation at RB2016 discussing how his life led to a passionate interest in the long-term maintenance of human health - and ultimately his decision to commit $10 million to our work.
Entrepreneur and biohacker Dave Asprey recently interviewed our Chief Science Officer, Dr. Aubrey de Grey, for the health podcast Bulletproof Radio. Their in-depth conversation covers a broad range of topics related to our current work and future plans.
Ending Aging Audiobook
Our general introduction to SENS research, Ending Aging, is now available in audiobook format. All profits will go to SENS Research Foundation. If Ending Aging is your first purchase as a new Audible member, we also get a $50 "bounty" - so please consider signing up!